No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
LFST240517P7000
- 0.35
- 0.000.00%
15min DelayClose May 14 16:00 ET
0.35High0.35Low
0.35Open0.35Pre Close1 Volume0 Open Interest7.00Strike Price35.00Turnover197.79%IV-10.01%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.35Time Value100Contract SizeAmericanOptions Type-0.3481Delta0.2740Gamma21.11Leverage Ratio-0.0868Theta-0.0002Rho-7.35Eff Leverage0.0025Vega
Intraday
- 5D
- 1D
News
LifeStance Health(LFST.US) Officer Sells US$362.57K in Common Stock
$LifeStance Health(LFST.US)$ Officer Cipollone Paula sold 50,278 shares of common stock on May 10, 13, 2024 at an average price of $7.21 for a total value of $362.57K.Source: Announcement What is stat
Lifestance Health Group Insider Sold Shares Worth $362,567, According to a Recent SEC Filing
Paula Cipollone, Chief Business Transformation Officer, on May 10, 2024, sold 50,278 shares in Lifestance Health Group (LFST) for $362,567. Following the Form 4 filing with the SEC, Cipollone has cont
Form 144 | LifeStance Health(LFST.US) Officer Proposes to Sell 348.63K in Common Stocks
SEC FILLINGS DISCLOSED/ May 13, $LifeStance Health(LFST.US)$ Officer PAULA CIPOLLONE intends to sell 48,278 shares of its common stock on May 13, with a total market value of approximately $348.63K.
Earnings Update: Here's Why Analysts Just Lifted Their LifeStance Health Group, Inc. (NASDAQ:LFST) Price Target To US$8.79
Barclays Reaffirms Their Sell Rating on Lifestance Health Group (LFST)
LifeStance Health | 10-Q: Quarterly report
Comments
LifeStance Health Group's positive outlook appears to be priced in, but its high growth potential at a fair price makes it an attractive investment. Higher cash flow is expected, potentially leading to a higher share valuation.
Is LifeStance Health Group, Inc. (NASDAQ:LFST) Potentially Undervalued? 1
LifeStance's CEO, Ken Burdick, is confident that Dr. DeLuca's skills will complement the board as they expand mental healthcare access. Dr. DeLuca is excited to join and help more patients receive personalized care.
1
LifeStance Health Group's high P/S ratio reflects market expectations of continued strong revenue growth. Investors may overpay if these expectations aren't met, but strong future revenue forecasts suggest a decrease in revenues is unlikely.
Despite top line growth, LifeStance Health Group is incurring a loss of US$145m on the EBIT line. The company's balance sheet, burdened with liabilities against cash, is deemed unfit and risky.
1
CEO Ken Burdick is confident in Dr. Ramtekkar's ability to drive exceptional patient and clinical outcomes, citing his commitment to clinical excellence. Dr. Ramtekkar is excited to join LifeStance and continue setting the bar for clinical excellence in mental health.
1
Read more